Literature DB >> 20193107

Research progress in cancer stem cells and their drug resistance.

Hong Yu1, Chang-Ming Zhang, Yong-Shou Wu.   

Abstract

Traditional theories suggest that tumor growth occurs when all tumor cells work together and result in proliferation, so treatment has been mainly directed against the majority of the cells in tumor tissue, which often relapse, metastasize, and lead to treatment failure. As cancer stem cells have been successfully isolated from different tumor tissues, in-depth study of their function in relation to traditional cancer treatment faces enormous challenges. At the same time, a new theoretical basis has been provided for the in-depth study of tumorigenesis and the evaluation of prognosis of cancer therapy. Also, new ideas have been introduced for cancer therapy. Therefore, radical treatment of cancer can be achieved through killing cancer stem cells. This article reviews the research progress on cancer stem cells and their drug resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20193107     DOI: 10.5732/cjc.009.10487

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


  5 in total

1.  Epithelial-mesenchymal Transition---A Hallmark of Breast Cancer Metastasis.

Authors:  Yifan Wang; Binhua P Zhou
Journal:  Cancer Hallm       Date:  2013-03

Review 2.  Epithelial-mesenchymal transition in breast cancer progression and metastasis.

Authors:  Yifan Wang; Binhua P Zhou
Journal:  Chin J Cancer       Date:  2011-09

3.  Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.

Authors:  So-Yeon Park; Min-Jin Kim; Sang-A Park; Jung-Shin Kim; Kyung-Nan Min; Dae-Kee Kim; Woosung Lim; Jeong-Seok Nam; Yhun Yhong Sheen
Journal:  Oncotarget       Date:  2015-11-10

4.  A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics.

Authors:  Donglai Lv; Shi-Cang Yu; Yi-Fang Ping; Haibo Wu; Xilong Zhao; Huarong Zhang; Youhong Cui; Bing Chen; Xia Zhang; Jianwu Dai; Xiu-Wu Bian; Xiao-Hong Yao
Journal:  Oncotarget       Date:  2016-08-30

5.  MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.

Authors:  Chao Fang; Yi-Xin Chen; Na-Yiyuan Wu; Ji-Ye Yin; Xiang-Ping Li; Hsuan-Shun Huang; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Sci Rep       Date:  2017-01-11       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.